Tibet Duo Rui Pharmaceutical Co., Ltd.

SZSE:301075 Stock Report

Market Cap: CN¥1.6b

Tibet Duo Rui Pharmaceutical Balance Sheet Health

Financial Health criteria checks 3/6

Tibet Duo Rui Pharmaceutical has a total shareholder equity of CN¥766.1M and total debt of CN¥236.7M, which brings its debt-to-equity ratio to 30.9%. Its total assets and total liabilities are CN¥1.1B and CN¥303.9M respectively.

Key information

30.9%

Debt to equity ratio

CN¥236.69m

Debt

Interest coverage ration/a
CashCN¥396.93m
EquityCN¥766.15m
Total liabilitiesCN¥303.86m
Total assetsCN¥1.07b

Recent financial health updates

No updates

Recent updates

What Tibet Duo Rui Pharmaceutical Co., Ltd.'s (SZSE:301075) 41% Share Price Gain Is Not Telling You

Oct 09
What Tibet Duo Rui Pharmaceutical Co., Ltd.'s (SZSE:301075) 41% Share Price Gain Is Not Telling You

Tibet Duo Rui Pharmaceutical's (SZSE:301075) Solid Earnings May Rest On Weak Foundations

May 01
Tibet Duo Rui Pharmaceutical's (SZSE:301075) Solid Earnings May Rest On Weak Foundations

Tibet Duo Rui Pharmaceutical Co.,Ltd. (SZSE:301075) Stock Rockets 44% As Investors Are Less Pessimistic Than Expected

Mar 08
Tibet Duo Rui Pharmaceutical Co.,Ltd. (SZSE:301075) Stock Rockets 44% As Investors Are Less Pessimistic Than Expected

Financial Position Analysis

Short Term Liabilities: 301075's short term assets (CN¥615.3M) exceed its short term liabilities (CN¥133.6M).

Long Term Liabilities: 301075's short term assets (CN¥615.3M) exceed its long term liabilities (CN¥170.2M).


Debt to Equity History and Analysis

Debt Level: 301075 has more cash than its total debt.

Reducing Debt: 301075's debt to equity ratio has increased from 20% to 30.9% over the past 5 years.

Debt Coverage: 301075's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 301075's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies